Efficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experience

Basit Öğe Kaydı
dc.contributor.authorKefeli, Umut
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorAkyol, Murat
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorCiltas, Aydin
dc.contributor.authorSevinc, Alper
dc.date.accessioned2024-04-24T17:28:03Z
dc.date.available2024-04-24T17:28:03Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: Sunitinib is a multi-targeted thyrosine kinase receptor inhibitor used in patients with advanced gastrointestinal stromal tumours (GISTs). We evaluated the efficacy and tolerability of sunitinib therapy in Turkish patients with GISTs. Methodology: Between January 2001 and April 2012, 57 patients who had progressive disease or experienced unacceptable toxicity during imatinib treatment from multiple centers were investigated retrospectively. Results: Thirty-three patients were male and 24 were female. The median age was 55 years (range; 16-84 years). Thirty-eight of the patients received imatinib for longer than 12 months, 13 patients received for 6-12 months, and 6 patients received for less than 6 months. The clinical benefit of sunitinib was 73.7%. Treatment-related adverse events were reported in 78% of the patients. Adverse events were generally mild to moderate in intensity The median progression free survival (PFS) and overall survival (OS) of the patients that received sunitinib were 10.8 months and 23.9 months, respectively. The time of imatinib usage and response to sunitinib were independent prognostic factors for PFS and OS. Also, tumor size was an independent prognostic factor for PFS. Conclusions: Sunitinib is an effective treatment in Turkish patients with GISTs, with a clinical benefit of 73.7% and shows an acceptable tolerabilityen_US
dc.identifier.doi10.5754/hge12692
dc.identifier.endpage652en_US
dc.identifier.issn0172-6390
dc.identifier.issue124en_US
dc.identifier.pmid23165189
dc.identifier.scopus2-s2.0-84879562900
dc.identifier.scopusqualityN/A
dc.identifier.startpage647en_US
dc.identifier.urihttps://doi.org/10.5754/hge12692
dc.identifier.urihttps://hdl.handle.net/11468/20307
dc.identifier.volume60en_US
dc.identifier.wosWOS:000320740700002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGistsen_US
dc.subjectSunitiniben_US
dc.subjectImatinib Intoleranceen_US
dc.titleEfficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experienceen_US
dc.titleEfficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu